What is Chimerix?
Chimerix, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of medicines designed to address critical unmet medical needs, primarily within the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog with potential applications in preventing serious viral infections in hematopoietic or stem cell transplant recipients, and treating adenovirus infection, smallpox, and BK virus infection in transplant patients. Chimerix is also advancing other candidates, including CMX521 for norovirus and CMX157 for HIV and hepatitis B virus infection. The company has established strategic partnerships, including a license agreement with ContraVir Pharmaceuticals and development support from BARDA for brincidofovir.
How much funding has Chimerix raised?
Chimerix has raised a total of $237.9M across 8 funding rounds:
Series A
$1M
Series B
$3.1M
Unspecified
$36.1M
Series C
$11M
Series D
$23.1M
Other Financing Round
$16.1M
Other Financing Round
$45M
Stock Offering
$102.5M
Series A (2002): $1M with participation from Asset Management Company
Series B (2003): $3.1M led by Sanderling Ventures
Unspecified (2003): $36.1M supported by National Institutes of Health
Series C (2004): $11M featuring Sanderling Ventures
Series D (2007): $23.1M backed by Canaan Partners, Frazier Healthcare Partners, Sanderling Ventures, and Alta Partners
Other Financing Round (2009): $16.1M with participation from Alta Partners, Canaan Partners, and Sanderling Ventures
Other Financing Round (2011): $45M led by New Leaf Venture Partners, Morningside Group, Pappas Ventures, Alta Partners, Canaan Partners, Frazier Healthcare Partners, and Sanderling Ventures
Stock Issuance/Offering (2013): $102.5M, investors not publicly disclosed
Key Investors in Chimerix
Canaan Partners
Canaan Partners is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health. With offices in the U.S. and Israel and billions of dollars under management, Canaan has funded hundreds of startups and supported dozens of IPOs and acquisitions.
Frazier Healthcare Partners
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.
Sanderling Ventures
Sanderling Ventures is a pioneering investment firm founded in 1979, specializing in building new biomedical companies. The firm has supported over 90 biomedical companies, focusing on early-stage financing and active management to achieve high rates of return for both entrepreneurs and investors. Their investment areas include small molecule therapeutics, biologics and vaccines, drug delivery, platform technologies, and medical devices. Sanderling Ventures is dedicated to fostering close partnerships with entrepreneurs to create significant companies in the biomedical sector.
What's next for Chimerix?
The recent major strategic investment signifies a strong vote of confidence in Chimerix's therapeutic pipeline and its potential to address significant public health challenges. Given the company's focus on serious viral infections and its established product candidates, this capital infusion is likely to fuel further clinical trials, regulatory submissions, and potentially commercialization efforts. The company's trajectory, marked by consistent funding rounds since its inception in 2000, indicates a sustained commitment to innovation in the biopharmaceutical sector. Future developments will likely center on advancing brincidofovir and its other investigational therapies through late-stage clinical development and towards market approval, positioning Chimerix as a key player in antiviral therapeutics.
See full Chimerix company page
